Viread

Antiretroviral Therapy, HIV, HIV + 5 more
Treatment
20 Active Studies for Viread

What is Viread

Tenofovir disoproxilThe Generic name of this drug
Treatment SummaryTenofovir disoproxil fumarate is an antiviral medication used to treat HIV and Hepatitis B. It is sold under the brand name Viread and is part of a class of drugs called nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is usually prescribed in combination with other medications. It was approved by the FDA in 2001.
Vireadis the brand name
image of different drug pills on a surface
Viread Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Viread
Tenofovir disoproxil
2001
154

Effectiveness

How Viread Affects PatientsTenofovir is an antiviral medicine used to treat HIV-1 and Hepatitis B infections. Lab tests show that it works by stopping the virus from making copies of itself. It was found to be effective with a concentration of 0.04 to 8.5 micrometers. Taking tenofovir with other antiviral medications has been shown to have an additional or synergistic effect in preventing the virus from replicating. Tenofovir has been approved by the FDA to treat HIV-1.
How Viread works in the bodyTenofovir is a medication used to treat HIV. It works by blocking an enzyme that helps the virus replicate, limiting its spread and allowing the virus to be managed. Tenofovir is absorbed in the body and converted to its active form, tenofovir diphosphate. This active form competes with natural deoxyribonucleotide substrate for binding to HIV-1 reverse transcriptase and hepatitis B polymerase, which then stops the virus from copying itself. In rare cases, HIV-1 may develop a resistance to tenofovir, meaning the virus can still replicate even with treatment.

When to interrupt dosage

The proposed measure of Viread is contingent upon the diagnosed ailment, like Anti-Retroviral Agents, High Risk Patients and Chronic Hepatitis B. The quantity of dosage is contingent upon the technique of delivery (e.g. Tablet or Tablet, film coated) cited in the following table.
Condition
Dosage
Administration
HIV-1 RNA Less Than or Equal to 100,000 copies/mL
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Antiretroviral Therapy
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
HIV
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
HIV
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Chronic Hepatitis B Infection
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
virologically-suppressed
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Obesity
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral
Obesity
300.0 mg, , 245.0 mg, 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, film coated - Oral, Tablet, film coated, , Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Powder, Powder - Oral, Granule, Granule - Oral

Warnings

There are 20 known major drug interactions with Viread.
Common Viread Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Tenofovir disoproxil is combined with Neomycin.
Tenofovir
Major
Tenofovir disoproxil may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Tenofovir disoproxil may increase the nephrotoxic activities of Tenofovir alafenamide.
Abacavir
Minor
Tenofovir disoproxil may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetaminophen
Minor
Tenofovir disoproxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Viread Toxicity & Overdose RiskBreastfeeding: The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breast-feed while taking tenofovir disoproxil. Carcinogenesis: Long-term studies in mice and rats found no evidence of cancer at doses up to 16 and 5 times the recommended human dose, respectively. However, female mice had an increase in liver adenomas at a higher dose. Pregnancy: Tenofovir disoproxil has been assigned to pregnancy Category B. Animal studies have found no harm to the fetus, but there are no adequate studies
image of a doctor in a lab doing drug, clinical research

Viread Novel Uses: Which Conditions Have a Clinical Trial Featuring Viread?

46 active trials are presently being conducted to assess Viread for its potential to substitute existing antiretroviral regimens for virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable regimen at the commencement of therapy, as well as for Chronic Hepatitis B and HIV (Human Immunodeficiency Virus) treatment.
Condition
Clinical Trials
Trial Phases
Antiretroviral Therapy
0 Actively Recruiting
Obesity
643 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3
HIV-1 RNA Less Than or Equal to 100,000 copies/mL
0 Actively Recruiting
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
virologically-suppressed
0 Actively Recruiting
Chronic Hepatitis B Infection
8 Actively Recruiting
Phase 3, Phase 2, Phase 1
HIV
0 Actively Recruiting
Obesity
0 Actively Recruiting

Viread Reviews: What are patients saying about Viread?

5Patient Review
11/18/2012
Viread for Chronic Hepatitis B
Viread is much easier to take than Intron A, however I have experienced some negative side effects such as poor appetite and constant joint popping. Additionally, I am concerned about the lack of information available regarding pregnancy while taking this medication.
5Patient Review
4/28/2012
Viread for Chronic Hepatitis B
I've only been taking this medication for a month, and I seem to catch colds really easily. Can I take a liver care alternative medication at the same time? I have also stabilized my sorrosis and gotten rid of my rashes.
5Patient Review
11/9/2015
Viread for Chronic Hepatitis B
I was positive for Chronic Hbv in 1990 and started a double-blind study for a new drug. I ended up being given Hepsera, but my viral load skyrocketed after the completion of the study. I started taking Viread and lamivudine, then switched to Viread 300mg and Baraclude (1mg, then .5mg). My viral load has been undetectable and my liver tests have been somewhat normal for over 7 years.
5Patient Review
1/8/2015
Viread for Chronic Hepatitis B
I've been feeling really terrible lately and my blood tests aren't improving. I'm considering quitting this treatment, but I don't know if the benefits will outweigh the bad side effects.
5Patient Review
4/24/2014
Viread for Chronic Hepatitis B
Though I experienced some daily side effects, such as a low-grade fever, body aches, dizziness, nausea, headaches, and nightmares, this treatment was ultimately effective.
5Patient Review
2/16/2015
Viread for Chronic Hepatitis B
No unpleasant side effects that I've noticed. In just three months, the treatment was undetectable in my system. The only downside is a dull pain on my right side occasionally.
5Patient Review
2/20/2015
Viread for Chronic Hepatitis B
I have chronic hepatitis B and have been taking this medication for over a year. My viral load has gone from 2 million to undetectable. I haven't experienced any negative side effects, but my vitamin D levels are on the low end of normal. So, I'm taking D to get the level up. There is also evidence that good levels of D can help prevent melanoma, which I recently had. Overall, I'm very pleased with the results except for the effect on my wallet!
5Patient Review
5/16/2008
Viread for HIV
5Patient Review
7/15/2008
Viread for HIV
4.7Patient Review
9/5/2015
Viread for Chronic Hepatitis B
I've been taking this medication for over five years and it's been great. My only complaint is that it sometimes makes me itch, but other than that I haven't had any issues.
4.3Patient Review
10/23/2009
Viread for HIV
I've been on Viread for a little over five years now, and it's working well for me in combination with Ziagen and Sustiva. The side effects are tolerable; I have mild lipodystrophy around my waist, high triglycerides, low good cholesterol, and high bad cholesterol. However, being undetectible is more important to me.
4.3Patient Review
4/2/2017
Viread for Chronic Hepatitis B
I've been using this medication for two years and it's done wonders for my health. That said, I am now experiencing extreme thirst, bone pain, weakness, and shortness of breath. I'm not sure if skipping a day here or there would help, but I definitely feel like my bones aren't as strong as they used to be.
4.3Patient Review
2/9/2014
Viread for Chronic Hepatitis B
I've been taking Viread for a year now and it's working great. I'm undetectable. But I'm wondering what will happen if I stop taking the medication or how long I have to take it for. My doctor says I have to take it for the rest of my life, but is that really true?
4.3Patient Review
2/3/2008
Viread for HIV
4Patient Review
4/22/2014
Viread for Chronic Hepatitis B
I've been taking this drug for a little over two months. I started experiencing some vomiting and nausea, but it's manageable. It can be hard to fall asleep sometimes, but I'm still active with sports. So far the viral count has dropped from 14million to 163IU/mL, which is good progress.
4Patient Review
6/22/2013
Viread for Chronic Hepatitis B
I've been taking Viread for two years and it's done a great job controlling the virus with relatively few side effects. The only issues I have are cold hands/feet, weird dreams, and occasional trouble sleeping; however, these are manageable.
4Patient Review
10/9/2014
Viread for Chronic Hepatitis B
I've been taking Viread 300mg daily since my liver transplant in 2010. I had chronic Hep B which turned into cancer, but this medication has helped me a lot. The only downside is some occasional heart palpitations, cold hands/feet, and diarrhea.
3.7Patient Review
3/28/2012
Viread for Chronic Hepatitis B
The medication is effective, but there are some drawbacks.
3.3Patient Review
3/31/2009
Viread for Chronic Hepatitis B
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about viread

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for Viread?

"Tenofovir is available as a generic and brand-name drug. The brand names for tenofovir are Viread and Vemlidy. Tenofovir comes in two forms: an oral tablet and an oral powder. The oral tablet form of tenofovir is approved to treat both HIV infection and chronic hepatitis b virus infection."

Answered by AI

What is Viread used for?

"Viread is a drug used to treat HIV and hepatitis b. It is taken in combination with other antiretroviral drugs. Viread is used to treat HIV-1 infection in adults and children aged 12 and over. It is also used to treat chronic hepatitis B."

Answered by AI

How long do you take Viread?

"You will usually need to take tenofovir for the rest of your life, even if you are feeling well. This is to keep your immune system healthy."

Answered by AI

Is Viread the same as Truvada?

"Viread is one medication in a pill that also includes another HIV medication called Emtriva. This pill is called Truvada. Viread is also part of other combination pills that are taken in one dose. These are for treatment of HIV and are called Single-dose treatment regimens (STRs). Atripla is one such pill that includes Viread as well as two other medications, TDF and Sustiva."

Answered by AI

Clinical Trials for Viread

Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.
Waitlist Available
Has No Placebo
UConn Health (+2 Sites)Linda S Pescatello, PhD
Have you considered Viread clinical trials? We made a collection of clinical trials featuring Viread, we think they might fit your search criteria.Go to Trials
Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Image of The Weight Control and Diabetes Research Center of The Miriam Hospital & Brown University in Providence, United States.

Self-Monitoring Strategies for Obesity

18 - 70
All Sexes
Providence, RI
This clinical trial is focused on testing dietary self-monitoring strategies used in behavioral obesity treatment. The goal is to determine which self-monitoring strategies are most useful for whom, at which points in treatment, and under what circumstances. Researchers will provide a 24-week online behavioral obesity treatment program, and will randomize participants to use one of 5 dietary self-monitoring strategies every two weeks. The five strategies include: recording all food and drink consumed and corresponding energy intake (i.e., "calories") on 7 days per week; recording all food and drink consumed and corresponding energy intake (i.e., "calories") on 3 days per week; self-monitoring of dietary lapses (i.e. any eating/drinking likely to cause weight gain or put weight loss at risk); smartwatch-based monitoring of energy intake (i.e., "calories"); and self-monitoring of body weight only via smart scale. Participants will: * Follow a 24-week online program for weight loss and health improvement * Use the assigned self-monitoring strategy every two weeks * Meet with the researchers periodically via online video call and provide research data by answering questions via periodic online surveys.
Recruiting
Has No Placebo
The Weight Control and Diabetes Research Center of The Miriam Hospital & Brown UniversityGraham Thomas, PhD
Have you considered Viread clinical trials? We made a collection of clinical trials featuring Viread, we think they might fit your search criteria.Go to Trials
Have you considered Viread clinical trials? We made a collection of clinical trials featuring Viread, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security